Current status of antifungal resistance and its impact on clinical practice
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Summary: Mortality linked to invasive fungal diseases remains very high despite the availability of novel antifungals and new therapeutic strategies. C andida albicans and A spergillus fumigatus account for most invasive mycosis produced by yeast or moulds, respectively. Other C andida non‐albicans are increasingly being reported and newly emerging, as well as cryptic, filamentous fungi often cause disseminated infections in immunocompromised hosts. Management of invasive fungal infections is becoming a challenge as emerging fungal pathogens generally show poor response to many antifungals. The ability of reference antifungal susceptibility testing methods to detect emerging resistance patterns, together with the molecular characterization of antifungal resistance mechanisms, are providing useful information to optimize the effectiveness of antifungal therapy. The current status of antifungal resistance epidemiology with special emphasis on the molecular resistant mechanisms that have been described in the main pathogenic fungal species are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 8×
“& Denning, D.W. (1998) In vitro activity of the echinocandin anti-”
BackgroundInfluentialAntifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 1×
“However, several recent reports of acquired resistance in clinical isolates of C. glabrata focus concern on this species because of a broad emergence of co-resistance over time to both azoles and echinocandins (Pfaller et al, 2012; Alexander et al, 2013).”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604
Self-citationResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Tortorano, A. M., Peman, J., Bernhardt, H., Klingspor, L., Kibbler, C. C., Faure, O., Biraghi, E., Canton, E., Zimmermann, K., Seaton, S., et al. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1103-y · Cited by 509
Mellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490
Self-citationPfaller, M. A., & Diekema, D. J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.00937-12 · Cited by 484
Arendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2012.03880.x · Cited by 451
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Possible Environmental Origin of Resistance of Aspergillus fumigatus to Medical Triazoles
Snelders, E., Huis in 't Veld, R. A. G., Rijs, A. J. M. M., Kema, G. H. J., Melchers, W. J. G., & Verweij, P. E. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.00231-09 · Cited by 423
Mechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422 · cited 1×
“Finally, biofilm formation has also been recognized as a potential factor in fungal drug resistance due to the production of an exopolymeric material that inhibits or restricts penetration of antifungal drugs (Taff et al, 2013).”
BackgroundMarichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Pfaller, M. A., Castanheira, M., Lockhart, S. R., Ahlquist, A. M., Messer, S. A., & Jones, R. N. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06112-11 · Cited by 377
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366 · cited 1×
“While antifungal drug resistance among C. albicans isolates remains low (Lockhart et al, 2012), C. glabrata and C. krusei have emerged as important and potentially antifungal resistant causes of candidaemia (Cleveland et al, 2012).”
BackgroundCornillet, A., Camus, C., Nimubona, S., Gandemer, V., Tattevin, P., Belleguic, C., Chevrier, S., Meunier, C., Lebert, C., Aupee, M., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/505870 · Cited by 361
Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351 · cited 1×
“Acquired resistance to AMB has been most extensively evaluated in yeasts and is associated with mutations in ERG3, which is linked to qualitative and quantitative alterations of membrane lipids and an absence of ergosterol (Kelly et al, 1997; Pinjon et al, 2003; Morio et al, 2012).”
Backgroundvan der Linden, J. W. M., Camps, S. M. T., Kampinga, G. A., Arends, J. P. A., Debets-Ossenkopp, Y. J., Haas, P. J. A., Rijnders, B. J. A., Kuijper, E. J., van Tiel, F. H., Varga, J., et al. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit320 · Cited by 342
Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12041 · Cited by 334
Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323
Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323
Wisplinghoff, H., Ebbers, J., Geurtz, L., Stefanik, D., Major, Y., Edmond, M. B., Wenzel, R. P., & Seifert, H. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.09.005 · Cited by 293 · cited 1×
“The differences in resistance associated with different species underscore the need for local epidemiological data to guide empirical therapy at the hospital level (Wisplinghoff et al, 2014).”
BackgroundCurrent Perspectives on Echinocandin Class Drugs
Perlin, D. S. (2011) · Future Microbiology · doi:10.2217/fmb.11.19 · Cited by 274 · cited 1×
“Also, elevated MIC values, unlinked to therapeutic failure, can occur and result from adaptive cell behaviour, which is FKS-independent and involves the molecular chaperone Hsp90 and the calcineurin pathway (Perlin, 2011).”
BackgroundFungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267
Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239 · cited 1×
“This mechanism has only been reported in clinical isolates of C. albicans resistant to FCZ, with gain-of-function mutations in the transcription factor UPC2 that led to increased expression of ERG11 (Dunkel et al, 2008; Flowers et al, 2012).”
BackgroundDunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J., & Rogers, P. D. (2008) · Eukaryotic Cell · doi:10.1128/ec.00103-08 · Cited by 236
Balashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225
Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2747-2750.2004 · Cited by 210
Self-citationKrogh-Madsen, M., Arendrup, M. C., Heslet, L., & Knudsen, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/500939 · Cited by 201 · cited 1×
“Although AMB resistance is still rare, recent reports of cross-resistance between AMB and azoles or CPF in Candida spp. are worrisome (Krogh-Madsen et al, 2006; Martel et al, 2010; Morio et al, 2012; Eddouzi et al, 2013; Forastiero et al, 2013).”
BackgroundMoran, G. P., Sanglard, D., Donnelly, S. M., Shanley, D. B., Sullivan, D. J., & Coleman, D. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1819 · Cited by 197
Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00348-10 · Cited by 168
Viscoli, C., Herbrecht, R., Akan, H., Baila, L., Sonet, A., Gallamini, A., Giagounidis, A., Marchetti, O., Martino, R., Meert, L., et al. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp355 · Cited by 154
Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China
Jiang, C., Dong, D., Yu, B., Cai, G., Wang, X., Ji, Y., & Peng, Y. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks481 · Cited by 153 · cited 1×
“Recently, combined mutations in both ERG11 and another enzyme of the ergosterol biosynthesis pathway (ERG3; encoding a C-5 sterol desaturase) seems to be emerging in C. albicans and C. tropicalis (Morio et al, 2012; Eddouzi et al, 2013; Forastiero et al, 2013; Jiang et al, 2013).”
BackgroundHerbrecht, R., Maertens, J., Baila, L., Aoun, M., Heinz, W., Martino, R., Schwartz, S., Ullmann, A. J., Meert, L., Paesmans, M., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.334 · Cited by 149 · cited 1×
“%) has been seen in allogeneic hematopoietic SCT patients (Herbrecht et al, 2010).”
BackgroundA Ser678Pro Substitution in Fks1p Confers Resistance to Echinocandin Drugs in Aspergillus fumigatus
Rocha, E. M. F., Garcia-Effron, G., Park, S., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00917-07 · Cited by 141
Forastiero, A., Mesa-Arango, A. C., Alastruey-Izquierdo, A., Alcazar-Fuoli, L., Bernal-Martinez, L., Pelaez, T., Lopez, J. F., Grimalt, J. O., Gomez-Lopez, A., Cuesta, I., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00477-13 · Cited by 131 · cited 3×
“Recently, combined mutations in both ERG11 and another enzyme of the ergosterol biosynthesis pathway (ERG3; encoding a C-5 sterol desaturase) seems to be emerging in C. albicans and C. tropicalis (Morio et al, 2012; Eddouzi et al, 2013; Forastiero et al, 2013; Jiang et al, 2013).”
BackgroundSelf-citationMorio, F., Pagniez, F., Lacroix, C., Miegeville, M., & Le Pape, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks186 · Cited by 120 · cited 3×
“Recently, combined mutations in both ERG11 and another enzyme of the ergosterol biosynthesis pathway (ERG3; encoding a C-5 sterol desaturase) seems to be emerging in C. albicans and C. tropicalis (Morio et al, 2012; Eddouzi et al, 2013; Forastiero et al, 2013; Jiang et al, 2013).”
BackgroundKelly, S. L., Lamb, D. C., Loeffler, J., Einsele, H., & Kelly, D. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1136 · Cited by 116 · cited 1×
“Some of them, such as Y132F/H and G464S/D, have been shown to confer azole resistance in C. albicans, C. dubliniensis and C. tropicalis (Kelly et al, 1991, 1999; Perea et al, 2002; Vandeputte et al, 2005; Park et al, 2011; Forastiero et al, 2013).”
BackgroundPark, B. J., Arthington-Skaggs, B. A., Hajjeh, R. A., Iqbal, N., Ciblak, M. A., Lee-Yang, W., Hairston, M. D., Phelan, M., Plikaytis, B. D., Sofair, A. N., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1287-1292.2006 · Cited by 113 · cited 1×
“Therefore, routine AMB testing for Candida species isolated from the bloodstream is probably not indicated (Park et al, 2006).”
BackgroundContribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., & Sanglard, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017589 · Cited by 110 · cited 2×
“Various mechanisms can lead to acquired resistance of Candida species to azole drugs, the most common being induction of efflux pumps, encoded by the ATP binding cassette (ABC)-transporter genes (CDR1 and CDR2, CgSNQ2) or to MDR belonging to the Major Facilitator transporter family genes (MFS) that lead to decreased d…”
BackgroundBeyda, N. D., Lewis, R. E., & Garey, K. W. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r020 · Cited by 109 · cited 3×
“…through three mechanisms: (i) acquired FKS mutations, which confer reduced GS sensitivity, elevated MICs, and are associated with clinical failure (Beyda et al, 2012), (ii) adaptive stress responses, which result in elevated cell wall chitin content and paradoxical growth in vitro (Walker et al,…”
BackgroundLewis, J. S., Wiederhold, N. P., Wickes, B. L., Patterson, T. F., & Jorgensen, J. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01144-13 · Cited by 101
Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., & Cannon, R. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01095-08 · Cited by 100 · cited 2×
“…of Haematology, 2014, 166, 471–484 the other hand, the innate FCZ resistance phenotype of C. krusei seems to be due to the low sensitivity of the drug target (Erg11p) to azole antifungals in combination with the constitutive expression of the multidrug efflux pump Abc1p (Lamping et al, 2009).”
BackgroundManagement of invasive fungal infections: a role for polyenes
Chandrasekar, P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq479 · Cited by 100
Transcriptional profiling of azole-resistant Candida parapsilosis strains
Silva, A. P., Miranda, I. M., Guida, A., Synnott, J., Rocha, R., Silva, R., Amorim, A., Pina-Vaz, C., Butler, G., & Rodrigues, A. G. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01127-10 · Cited by 86
Invasive fungal infections in acute leukemia
Bhatt, V. R., Viola, G. M., & Ferrajoli, A. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711410098 · Cited by 71
Jensen, R. H., Johansen, H. K., & Arendrup, M. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-12 · Cited by 47 · cited 1×
“…therapy has been associated with amino acid substitutions in FKS1 (C. albicans, C. tropicalis, C. krusei, C. glabrata, C. lusitaniae) (Park et al, 2005; Garcia-Effron et al, 2009; Desnos-Ollivier et al, 2011; Jensen et al, 2013) and FKS2 (C. glabrata) (Garcia-Effron et al, 2009; Lewis et al, 2013).”
Azole Antifungal Resistance Today: Focus on Aspergillus
Bowyer, P., Moore, C. B., Rautemaa, R., Denning, D. W., & Richardson, M. D. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-011-0218-4 · Cited by 44 · cited 1×
“The real incidence of resistance in A. fumigatus is relatively unknown but since the first azole resistant isolate was detected in 1997 in the UK, azole resistance has been increasingly reported in many other countries (Denning et al, 1997; Bowyer et al, 2011).”
Background
Cited by
Matsubara, V. H., Wang, Y., Bandara, H. M. H. N., Mayer, M. P. A., & Samaranayake, L. P. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7527-3 · Cited by 206
“, as the biofilm cells exhibit greater resistance to antifungals and host defenses compared to their planktonic or suspended counterparts (Alcazar-Fuoli and Mellado 2014).”
BackgroundFungal persister cells: The basis for recalcitrant infections?
Wuyts, J., Van Dijck, P., & Holtappels, M. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007301 · Cited by 136
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
“This has the potential to contribute to clinical resistance [55] and it is extremely important to differentiate these low-level drug tolerance and adaptive mechanisms from the Fks1-mediated mechanisms that have been observed in clinical isolates and can result in treatment failure [55,129].”
BackgroundInfluentialThe Rpd3/Hda1 family of histone deacetylases regulates azole resistance in Candida albicans
Li, X., Cai, Q., Mei, H., Zhou, X., Shen, Y., Li, D., & Liu, W. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv070 · Cited by 64
Gupta, P. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10467.5395 · Cited by 43
Metadata
- Authors
- Alcazar‐Fuoli, L., & Mellado, E.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2014-04-18
- Volume
- 166
- Issue
- 4
- Pages
- 471-484
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W1964646367
- Cited by
- 117
- References
- 53
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.